Toronto-based venture investment firm backing early-stage technologies for mental health and wellbeing. Its neuroscience and central-nervous-system focus spans novel drug therapeutics, psychedelic-assisted therapies, digital health, medical devices and wearables, emphasizing evidence-backed treatments, prevention and early intervention. Its published portfolios distinguish Fund I and Fund II; these existing vehicles are not presented as newly launched funds in 2024.
Founded
—
Type
Venture capital
Funds3
Noetic Fund I——
Published first Noetic portfolio vehicle investing in early-stage mental-health and neuroscience companies, including therapeutics, medical devices and digital health. Public close date and total fund size have not been established.
Noetic Fund II (US), LP——
Delaware limited partnership acting as the US vehicle in Noetic Fund II’s structure, with GHP Noetic Cayman GP Ltd. as general partner. An April 2024 SEC amendment reports cumulative securities sold, not a newly closed 2024 fund.
Noetic Fund II Cayman Master, LP——
Noetic’s second neuroscience and mental-health investment vehicle. The manager identifies the Cayman master partnership as the majority investor leading CaaMTech’s September 2021 Series A; that issuer financing does not establish the fund close date or total fund size.
